The DOI matches its Crossref record.
Urinary Angiotensinogen as a Marker of Intrarenal Angiotensin II Activity Associated with Deterioration of Renal Function in Patients with Chronic Kidney Disease
Open accessAbstract
In chronic kidney disease (CKD), enhanced intrarenal angiotensin II (AngII) is involved in deterioration of renal function, but it is difficult to measure it. For assessment of the potential of urinary angiotensinogen as a marker of intrarenal AngII activity, the correlation of plasma and urinary renin-angiotensin system components, including angiotensinogen, with deterioration of renal function was investigated in 80 patients who had CKD and were not treated with AngII blocking agents. Changes that were induced by 14 d of losartan treatment (25 mg/d) were also measured in 28 patients. Angiotensinogen was measured by RIA of AngI after incubation with renin. Urinary angiotensinogen levels were greater in patients with low estimated GFR and elevated urinary protein and type IV collagen and correlated with renal AngII and type I collagen immunostaining intensities. The risk for deterioration of renal function (i.e., estimated GFR decline of >2.5 ml/min per yr) during a mean follow-up period of 23 mo (maximum 43 mo) was associated with urinary angiotensinogen of >3.0 nmol AngI equivalent per 1 g of urinary creatinine (AngI Eq/g Cre) at enrollment (hazard ratio 3.52). The event-free survival for deterioration of renal function was better in patients with urinary angiotensinogen <3.0 nmol AngI Eq/g Cre than those >3.0 nmol AngI Eq/g Cre. Losartan reduced urinary and plasma angiotensinogen, urinary protein and type IV collagen, and systolic BP, despite concomitant increases in plasma renin and AngII. These data suggest that urinary angiotensinogen is a potentially suitable marker of intrarenal AngII activity associated with increased risk for deterioration of renal function in patients with CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cardiac Fibrosis: The Fibroblast Awakens
Travers, J. G., Kamal, F. A., Robbins, J., Yutzey, K. E., & Blaxall, B. C. (2016) · Circulation Research · doi:10.1161/circresaha.115.306565 · Cited by 1,596
Biomarkers of AKI: A Review of Mechanistic Relevance and Potential Therapeutic Implications
Alge, J. L., & Arthur, J. M. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12191213 · Cited by 294
Role of the Intrarenal Renin-Angiotensin-Aldosterone System in Chronic Kidney Disease
Siragy, H. M., & Carey, R. M. (2010) · American Journal of Nephrology · doi:10.1159/000313363 · Cited by 293
Circadian rhythm of blood pressure and the renin-angiotensin system in the kidney
Ohashi, N., Isobe, S., Ishigaki, S., & Yasuda, H. (2017) · Hypertension Research · doi:10.1038/hr.2016.166 · Cited by 78
Self-citation
Metadata
- Authors
- Yamamoto, T., Nakagawa, T., Suzuki, H., Ohashi, N., Fukasawa, H., Fujigaki, Y., Kato, A., Nakamura, Y., Suzuki, F., & Hishida, A.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2007-05
- Volume
- 18
- Issue
- 5
- Pages
- 1558-1565
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2117440871
- Cited by
- 194
- References
- 0
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Urinary Angiotensinogen as a Marker of Intrarenal Angiotensin II Activity Associated with Deterioration of Renal Function in Patients with Chronic Kidney Disease. https://app.cochat.ai/papers/10.1681/asn.2006060554
- The paper
- Yamamoto, T., Nakagawa, T., Suzuki, H., Ohashi, N., Fukasawa, H., Fujigaki, Y., Kato, A., Nakamura, Y., Suzuki, F., & Hishida, A. (2007). Urinary Angiotensinogen as a Marker of Intrarenal Angiotensin II Activity Associated with Deterioration of Renal Function in Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2006060554
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.